# Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

> **NCT06958796** · PHASE4 · RECRUITING · sponsor: **Camille N. Kotton, MD** · enrollment: 80 (estimated)

## Conditions studied

- Cytomegalovirus
- Organ Transplant
- Kidney Transplant; Complications
- Liver Transplant Complications
- Simultaneous Liver-Kidney Transplantation; Complications

## Interventions

- **DRUG:** Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months

## Key facts

- **NCT ID:** NCT06958796
- **Lead sponsor:** Camille N. Kotton, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-05-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06958796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06958796, "Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06958796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*